Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations

European Journal of Nuclear Medicine
R A ClaessensF H Corstens

Abstract

Recently a new linker - hydrazinonicotinate (HYNIC) - was introduced for labelling of proteins and peptides with technetium-99m. HYNIC and other linkers have been used for labelling of human non-specific polyclonal immunoglobulin G (hIgG) with 99mTc for the detection of infections. In this study we compared the tissue distribution of three different 99mTc-hIgG preparations in groups of five Wistar rats with a focal intramuscular infection with Staphylococcus aureus. We compared 99mTc-HYNIC-hIgG with 99mTc-hIgG labelled via the so-called Schwarz method (reduction of disulphide bonds) and with the 99mTc-labelled commercially available Technescan-HIG. Unlike the HYNIC linker, in the two other labelling methods free sulph-hydryl groups are involved in the binding of 99mTc. High-performance liquid chromatography analysis of the labelled preparations and of plasma samples revealed aggregate or polymer formation in all three agents; this was least pronounced in the product labelled by means of the Schwarz method. The tested preparations did not show signs of degradation in vitro. The difference in linker chemistry was reflected in the tissue distribution. Thus the biodistribution of 99mTc-HYNIC-hIgG was significantly different from th...Continue Reading

References

Apr 1, 1979·Analytical Biochemistry·P W RiddlesB Zerner
Jul 1, 1992·Nuclear Medicine Communications·G MardirossianD J Hnatowich
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W J OyenF H Corstens
Oct 5, 1989·The New England Journal of Medicine·R H RubinH W Strauss
Oct 1, 1988·Seminars in Nuclear Medicine·A J FischmanG M LaMuraglia
Jul 1, 1982·Seminars in Nuclear Medicine·L R Chervu, M D Blaufox
Apr 1, 1993·Seminars in Nuclear Medicine·F H CorstensW S Becker
Nov 1, 1995·Nuclear Medicine Communications·K VerbekeA Verbruggen

❮ Previous
Next ❯

Citations

Jan 12, 2002·Nuclear Medicine and Biology·Guozheng LiuDonald J Hnatowich
Aug 28, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Alberto SignoreFrancesco Scopinaro
Apr 1, 1997·Free Radical Research·L van der LaanR J Goris
Jul 18, 2008·Journal of Southern African Studies·P Delius
Dec 26, 2001·Chemical Reviews·S Liu, D S Edwards

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.